{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transplant+Bone+Disease&page=2", "query": { "condition": "Transplant Bone Disease", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transplant+Bone+Disease&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T13:13:36.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07249346", "title": "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplasia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Myeloablative conditioning regimen", "type": "DRUG" }, { "name": "Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hannah Choe, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2026-06-01", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07249346" }, { "nct_id": "NCT01500161", "title": "Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Hodgkins Disease", "Non-Hodgkins Lymphoma", "Aplastic Anemia", "Multiple Myeloma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Oncology Cancer Center", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2011-11", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Amarillo, Texas", "locations": [ { "city": "Amarillo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500161" }, { "nct_id": "NCT00002943", "title": "Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extragonadal Germ Cell Tumor", "Ovarian Cancer", "Testicular Germ Cell Tumor", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 11, "start_date": "1993-02", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002943" }, { "nct_id": "NCT02231710", "title": "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Immune Deficiency Disorders", "Hemophagocytic Lymphohistiocytosis", "Inherited Bone Marrow Failure Syndrome", "Hemoglobinopathies", "Metabolic Disorders" ], "interventions": [ { "name": "BPX-501 and Rimiducid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "4 Months to 55 Years" }, "enrollment_count": 1, "start_date": "2015-02", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2024-03-25", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231710" }, { "nct_id": "NCT01008462", "title": "Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Hypodiploidy", "Loss of Chromosome 17p", "Plasma Cell Leukemia", "Progression of Multiple Myeloma or Plasma Cell Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Small Lymphocytic Lymphoma", "t(14;16)", "t(4;14)", "T-Cell Prolymphocytic Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 16, "start_date": "2010-03-18", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 2, "location_summary": "Seattle, Washington • Milwaukee, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008462" }, { "nct_id": "NCT00578942", "title": "Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Myeloma", "Leukemia", "Myelodysplasia", "Solid Tumors" ], "interventions": [ { "name": "Campath Purged Non-myeloablative ASCT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 48, "start_date": "2005-05", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578942" }, { "nct_id": "NCT00002942", "title": "Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 136, "start_date": "1996-06", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002942" }, { "nct_id": "NCT06013423", "title": "Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Hematopoietic and Lymphatic System Neoplasm", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Chronic Myeloid Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 54, "start_date": "2024-07-23", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013423" }, { "nct_id": "NCT05405374", "title": "OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lumbar Spine Disease", "Lumbar Spondylolisthesis", "Lumbar Spine Instability", "Lumbar Spondylosis", "Degenerative Disc Disease" ], "interventions": [ { "name": "OSTEOAMP", "type": "OTHER" }, { "name": "Infuse", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Bioventus LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 101, "start_date": "2022-05-06", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2023-08-28", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Wichita, Kansas • Paducah, Kentucky + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Paducah", "state": "Kentucky" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405374" }, { "nct_id": "NCT00531310", "title": "Reduced Intensity AlloSCT in(CML) With Persistent Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Reduced Intensity Conditioning, Busulfan and Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 5, "start_date": "2003-01", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2011-04-14", "last_synced_at": "2026-07-24T13:13:36.125Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531310" } ] }